CTLA4 and lung cancer: A recent study found that miR‐33a overexpression linked to the low levels of PD‐1 and Cytotoxic T‐lymphocyte‐associated antigen 4 (CTLA‐4) in low‐grade and early‐stage lung cancer patients,47 suggesting that miR‐33a could serve as a biomarker to predict the effectiveness of anti‐PD‐1 and anti‐CTLA‐4 drugs in lung cancer patients.